BCL2 and neoplasm: This resulted in increased production of IL-6 by IL-17 receptor-expressing tumor and tumor-associated stromal cells and concomitantly increased STAT3 signaling and production of pro-survival Bcl-2 and Bcl-xL in melanoma cells [186].